AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

37.420

+0.9802.69%

Volume:630.49K

Turnover:23.74M

Market Cap:54.85B

PE:2.77

High:37.510

Open:37.420

Low:37.360

Close:36.440

Loading ...

Overview Company News Filings

With 69% ownership, ResMed Inc. (NYSE:RMD) boasts of strong institutional backing

Simply Wall St.

Top brokers name 3 ASX shares to buy next week

5 easy steps to making $1 million from ASX shares

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

ResMed Inc. Stock Falls Thursday, Underperforms Market

ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket

BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up

ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up

ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls

STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook

Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles

Looking to bag the record high ResMed dividend? You better hurry!

I'd invest $25 a week in ASX shares for a passive income in retirement

Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":37.42,"timestamp":1741649062294,"preClose":36.44,"halted":0,"volume":630487,"delay":0,"changeRate":0.026894,"change":0.98,"floatShares":145639189,"shares":1465797180,"eps":13.500514,"lyrEps":11.068389,"pbRate":6.55,"amount":23742472,"amplitude":0.004116,"volumeRatio":7.396835,"dividePrice":3.219662,"prevYearClose":36.689,"fiveDayClose":37.77,"twentyDayClose":37.737},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145639189,"roa":"13.89%","roe":"25.65%","lyrEps":11.068389,"volumeRatio":7.396835,"shares":1465797180,"dividePrice":3.219662,"high":37.51,"amplitude":0.004116,"preClose":36.44,"low":37.36,"week52Low":26.807,"pbRate":"6.55","psRate":"6.98","week52High":40.661,"institutionHeld":0,"latestPrice":37.42,"committee":-0.68272,"eps":13.500514030236134,"divideRate":0.085691,"volume":630487,"delay":0,"ttmEps":13.500514030236134,"open":37.42,"prevYearClose":36.689,"prevWeekClose":35.88,"prevMonthClose":37.12,"prevQuarterClose":36.689,"fiveDayClose":37.77,"twentyDayClose":37.737,"sixtyDayClose":38.196},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"},{"date":"2024-02-07","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-01-25","type":"dividend","market":"AU","newRecordDate":"2024-02-08","defaultRemindTime":1707260400000,"name":"Resmed DRC","recordDate":"2024-03-14","payableDate":"2024-02-08","currency":"USD","dateTimestamp":1707224400000,"payDate":"2024-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510041949","title":"With 69% ownership, ResMed Inc. (NYSE:RMD) boasts of strong institutional backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2510041949","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510041949?lang=en_us&edition=fundamental","pubTime":"2025-02-09 22:00","pubTimestamp":1739109613,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies ResMed's stock price is sensitive to their trading actions. A look at the shareholders of ResMed Inc.  can tell us which group is most powerful. With 69% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of ResMed.The definition of company insiders can be subjective and does vary between jurisd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/69-ownership-resmed-inc-nyse-140013728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4082","BK4567","NYSE","RMD.AU","LU2008162690.USD","BK4585","BK4548","LU2177674079.SGD","BK4588","BK7007","RMD","BK4504","BK7501"],"gpt_icon":0},{"id":"2510064849","title":"Top brokers name 3 ASX shares to buy next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2510064849","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510064849?lang=en_us&edition=fundamental","pubTime":"2025-02-09 06:10","pubTimestamp":1739052600,"startTime":"0","endTime":"0","summary":"It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Her","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/09/top-brokers-name-3-asx-shares-to-buy-next-week-9-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1791807156.HKD","BK4550","BK4585","BK7007","IE00BFXG1179.USD","IE00B19Z3581.USD","LU1668664300.SGD","BK4533","BK7501","BK4127","LU2237443382.USD","IE0034235188.USD","LU2237443465.HKD","LU2237443622.USD","BK4504","BK4516","BK7115","BK4588","IE00BSNM7G36.USD","BK7101","LU2237443978.SGD","LU2237443549.SGD","LU0106831901.USD","IE0002270589.USD","BK4552","DRO.AU","IE0004091025.USD","LU2237438978.USD","LU2237443895.HKD","IE00B19Z3B42.SGD","IE0004086264.USD","RMD.AU","SDF.AU"],"gpt_icon":1},{"id":"2509778239","title":"5 easy steps to making $1 million from ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778239","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509778239?lang=en_us&edition=fundamental","pubTime":"2025-02-08 02:35","pubTimestamp":1738953300,"startTime":"0","endTime":"0","summary":"Investing in the share market can be one of the most effective ways to build long-term wealth, and with the right strategy, reaching $1 million is very achievable. But success doesn't happen overnight","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/08/5-easy-steps-to-making-1-million-from-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","BK7155","BK7511","BK7508","TLS.AU","BK7099","BK7042","BK7041","RMD.AU","CSL.AU","BK7153","BK7501","BK7510","GMG.AU","BK7067","WES.AU"],"gpt_icon":1},{"id":"2509745879","title":"QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand","url":"https://stock-news.laohu8.com/highlight/detail?id=2509745879","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509745879?lang=en_us&edition=fundamental","pubTime":"2025-02-07 19:50","pubTimestamp":1738929000,"startTime":"0","endTime":"0","summary":"QIAGEN N.V.’s QGENfourth-quarter 2024adjusted earnings per share  were 61 cents, the same at the constant exchange rate . The reported figure increased 11% from the 2023 comparable figure. However, it fell short of the Zacks Consensus Estimate by 1.6%.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.On a GAAP basis, EPS in the fourth quarter was 39 cents compared with 42 cents in the year-ago period.For the full year, adjusted earnings were $2.18 per share, up 5% from the year-ago period’s levels.Net sales in the fourth quarter were $521.2 million . The top line marginally beat the Zacks Consensus Estimate by 0.1%. Sales at CER were $525 million, ahead of the outlook of at least $520 million.Total revenues for 2024 were $1.98 bil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qiagen-q4-earnings-miss-stock-115000161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QGEN","RMD","RMD.AU","CAH","BIO"],"gpt_icon":0},{"id":"2509574587","title":"PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2509574587","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509574587?lang=en_us&edition=fundamental","pubTime":"2025-02-07 19:47","pubTimestamp":1738928820,"startTime":"0","endTime":"0","summary":"Phibro Animal HealthPAHC delivered adjusted earnings per share  of 54 cents in the second quarter of fiscal 2025compared with 33 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 28.5%.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.Without adjustments, the GAAP EPS in the quarter was 8 cents compared with 3 cents in the prior-year period.Net sales in the quarter totaled $309.3 million, up 23.8% from the year-ago quarter’s level. The figure also exceeded the Zacks Consensus Estimate by 3.6%.Following the announcement, PAHC shares fell 2.8% in the after-hours trading yesterday.The company conducts its operations via three segments — Animal Health, Mineral Nutrition and Performance Products.Net vaccine sales showed a year-over-year rise of 12%, primarily due to the continued growth of poultry products in Latin America, along with an increase in international demand.Cumulative net cash provided by operating activities at the en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pahc-stock-falls-despite-q2-114700771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAH","ZTS","RMD.AU","BIO","PAHC","RMD"],"gpt_icon":0},{"id":"2509787744","title":"ResMed Inc. Stock Falls Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2509787744","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509787744?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:56","pubTimestamp":1738878960,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  shed 2.23% to $237.18 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.36% to 6,083.57 and the Dow Jones Industrial Average  falling 0.28% to 44,747.63.ResMed Inc. closed 9.83% below its 52-week high of $263.05, which the company achieved on January 30th.Trading volume  eclipsed its 50-day average volume of 875,049.Data source: Dow Jones Market Data, FactSet. Data compiled February 6, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2509200232","title":"ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2509200232","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509200232?lang=en_us&edition=fundamental","pubTime":"2025-02-07 01:38","pubTimestamp":1738863480,"startTime":"0","endTime":"0","summary":"Zimmer Biomet Holdings, Inc.ZBH posted fourth-quarter 2024adjusted earnings per share  of $2.31, beating the Zacks Consensus Estimate by a penny. The adjusted figure increased 5% year over year.See the Zacks Earnings Calendar to stay ahead of market-making news.The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, certain litigation charges and European Union Medical Device Regulation-related charges, among others.On a reported basis, the company registered earnings of $1.20 per share, down 40.3% year over year.For the full year, adjusted EPS was $8.00, a 5.9% improvement from 2023. The adjusted figure beat the Zacks Consensus Estimate by a close margin of 0.1%.Following the announcement, shares of ZBH dropped more than 1.3% in pre-market trading today.Fourth-quarter net sales of $2.02 billion increased 4.3%  year over year. The figure exceeded the Zacks Consensus Estimate by 0.6%.Zimmer Biomet Holdings, Inc. Price, Consensus and E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zbhs-q4-earnings-beat-margins-173800332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZBH","CAH","DGX","RMD.AU","RMD"],"gpt_icon":1},{"id":"2509023412","title":"BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2509023412","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509023412?lang=en_us&edition=fundamental","pubTime":"2025-02-07 00:49","pubTimestamp":1738860540,"startTime":"0","endTime":"0","summary":"Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share  of $3.43 in the first quarter of fiscal 2025, up 27.9% year over year. The figure topped the Zacks Consensus Estimate by 15.1%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.GAAP EPS for the quarter was $1.04, reflecting an improvement of 8.3% from the year-ago figure.BD registered revenues of $5.17 billion in the fiscal first quarter, up 9.8% year over year. The figure surpassed the Zacks Consensus Estimate by 1.3%.At constant exchange rate , revenues climbed 9.6%, while organic revenue change was 3.9% year over year.In the first quarter of fiscal 2025, revenues in the United States improved 12% to $3.08 billion. This compares to the Zacks Consensus Estimate of revenues of $2.94 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bd-stock-falls-pre-market-164900724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TWST","RMD","RMD.AU","BDX","CAH"],"gpt_icon":0},{"id":"2509203493","title":"ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2509203493","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509203493?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:51","pubTimestamp":1738853460,"startTime":"0","endTime":"0","summary":"Accuray IncorporatedARAY reported second-quarter fiscal 2025 earnings per share of 2 cents against the year-ago period’s loss of 10 cents. The bottom line surpassed the Zacks Consensus Estimate by 300%.Find the latest EPS estimates and surprises onZacks Earnings Calendar.Accuray registered quarterly revenues of $116.2 million, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 4.7%.The overall top-line growth was driven by robust growth in product revenue and solid demand for its CyberKnife system.ARAY’s shares moved north 6.8% and closed at $2.49 on Wednesday. The company’s shares have gained 66% in the past six months compared with theindustry’s 6.7% growth. The broader S&P 500 Index has gained 16.5% in the same time frame.Accuray derives revenues from two sources — Products and Services.Services revenues declined 1.3% year over year to $54.9 million.Accuray’s second-quarter fiscal 2025 earnings and revenues beat their respective estimates. Per the second-quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aray-stock-q2-earnings-revenues-145100215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ARAY","CAH","RMD","RMD.AU"],"gpt_icon":0},{"id":"2509203438","title":"ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2509203438","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509203438?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:49","pubTimestamp":1738853340,"startTime":"0","endTime":"0","summary":"Align Technology, Inc. ALGN delivered fourth-quarter 2024 adjusted earnings per share  of $2.44, up 0.8% from the year-ago level. The reported figure topped the Zacks Consensus Estimate by 0.4%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was $1.39, reflecting a decline of 15.2% from $1.64 in the comparable period of 2023.Full-year adjusted EPS was $9.33, reflecting an 8.4% increase from the 2023 level. The figure surpassed the Zacks Consensus Estimate by 0.1%.Following the earnings announcement, ALGN stock plunged 0.8% yesterday.The top line increased 4% year over year to $995.2 million but missed the Zacks Consensus Estimate by 0.2%. Revenues were favorably impacted by foreign exchange of approximately $0.9 million.Full-year revenues totaled $4.00 billion, up 3.5% from the 2023 level. The figure was in line with the Zacks Consensus Estimate.Align Technology provided its financial outlook for full-year 2025. It also provided a guidanc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/algn-q4-earnings-top-estimates-144900613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["DGX","CAH","RMD.AU","RMD","ALGN"],"gpt_icon":0},{"id":"2509433203","title":"STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2509433203","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509433203?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:48","pubTimestamp":1738853280,"startTime":"0","endTime":"0","summary":"STERIS plc STE reported third-quarter fiscal 2025 adjusted earnings per share  of $2.32, up 9.9% from the year-ago quarter’s figure. The figure is in line with the Zacks Consensus Estimate.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.The company’s GAAP EPS was $1.75, up 17.4% from the year-ago level of $1.49.Following the earnings announcement, STE stock rose 0.01% at after-market trading yesterday.Revenues of $1.37 billion from continuing operations increased 5.6% year over year. The figure missed the Zacks Consensus Estimate by 0.7%.The company operates under three segments — Healthcare, Applied Sterilization Technologies  and Life Sciences.Revenues at AST improved 10% to $258.1 million . This performance reflected 10% growth in service revenues, offset by a 5% decline in capital equipmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ste-q3-earnings-line-25-144800139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD","STE","DGX","HONE","CAH"],"gpt_icon":0},{"id":"2509820346","title":"CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2509820346","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509820346?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:44","pubTimestamp":1738853040,"startTime":"0","endTime":"0","summary":"CONMED CorporationCNMD delivered fourth-quarter 2024 adjusted earnings per share  of $1.34, which beat the Zacks Consensus Estimate of $1.20 by 11.7%. The bottom line improved 26.4% from the year-ago level.Find the latest EPS estimates and surprises onZacks Earnings Calendar.GAAP EPS for the quarter was $1.08 compared with $1.50 in the year-ago period.CONMED’s revenues totaled $345.9 million, up 5.8% year over year. The top line beat the Zacks Consensus Estimate by 1.4%. At constant exchange rate , revenues increased 6%.The top line was driven primarily by strength in the General Surgery segment and continued demand for innovative products like AirSeal.For 2024, CNMD’s revenues totaled $1.31 billion, up 5% year over year on a reported basis and 5.3% on a constant currency basis.Revenues in the Orthopedic Surgery segment totaled $139 million, up 1.8% from the year-ago level on a reported basis. At CER, revenues increased 2.4%.Sales improved 5.2% on a reported basis in the United States.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cnmds-q4-earnings-sales-beat-144400596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CNMD","RMD","RMD.AU","CAH"],"gpt_icon":0},{"id":"2509203490","title":"Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles","url":"https://stock-news.laohu8.com/highlight/detail?id=2509203490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509203490?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:17","pubTimestamp":1738851420,"startTime":"0","endTime":"0","summary":"Labcorp HoldingsLH, or Labcorp, reported adjusted earnings per share  of $3.45 in the fourth quarter of 2024. The figure rose 4.5% from the year-ago level.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line beat the Zacks Consensus Estimate by 1.5%.On a GAAP basis, EPS in the fourth quarter was $1.70 compared to a loss of $1.95 in the year-ago period.For the full year, adjusted earnings were $14.57 per share, up 7.4% from the year-ago period. The metric topped the Zacks Consensus Estimate by 0.4%.The increase was due to organic revenues of 5.4%, acquisitions, net of divestitures, of 4% and a foreign currency translation gain of 0.3%. The 5.4% increase in organic revenues was driven by a 6.2% rise in the company's organic Base Business, partially offset by a 0.8% decline in PCR testing .Total revenues for 2024 were $13.01 billion, up 7% from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/labcorp-q4-earnings-revenues-beat-141700732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LH","RMD.AU","RMD","CAH"],"gpt_icon":0},{"id":"2509429837","title":"Looking to bag the record high ResMed dividend? You better hurry!","url":"https://stock-news.laohu8.com/highlight/detail?id=2509429837","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509429837?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:54","pubTimestamp":1738806857,"startTime":"0","endTime":"0","summary":"Buying a stock simply for its passive income can backfire if the company's share price goes backwards over the year. So, atop the pending ResMed dividend, is the ASX 200 healthcare stock a good buy?Taking a look in the rearview, the ResMed share price has gained an impressive 32.0% over the past 12 months. As for what lies ahead, Goldman Sachs has a bullish outlook for the company. Following ResMed's quarterly update, the broker noted that \"the result reinforced the various growth levers which RMD has greater control over\". Goldman Sachs reiterated its buy rating on ResMed shares with a $49.00 price target. That represents a potential upside of almost 27% from the current $38.64 a share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/06/looking-to-bag-the-record-high-resmed-dividend-you-better-hurry/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00BSNM7G36.USD","BK4533","LU2237443382.USD","LU2237443549.SGD","BK4588","LU2008162690.USD","BK4516","BK4585","IE00B19Z3B42.SGD","RMD","IE0002270589.USD","IE0004091025.USD","LU0106831901.USD","BK4127","LU2177674079.SGD","LU2237443895.HKD","LU1791807156.HKD","BK4552","BK4548","BK4504","XJO.AU","IE0004086264.USD","IE0034235188.USD","IE00BFXG1179.USD","BK4550","RMD.AU","BK7007","BK4567","IE00B19Z3581.USD","LU2237443622.USD","LU2237443465.HKD","LU2237443978.SGD","LU1668664300.SGD","LU2237438978.USD","BK7501","BK4082"],"gpt_icon":0},{"id":"2509258044","title":"I'd invest $25 a week in ASX shares for a passive income in retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2509258044","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509258044?lang=en_us&edition=fundamental","pubTime":"2025-02-06 03:40","pubTimestamp":1738784442,"startTime":"0","endTime":"0","summary":"Investing small amounts consistently in high-quality ASX shares could be a simple yet powerful way to build a passive income for retirement. Even if the stock market is sitting near record highs, ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/06/id-invest-25-a-week-in-asx-shares-for-a-passive-income-in-retirement/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7042","BK7501","BK7046","CSL.AU","BK7511","BK7508","MQG.AU","BK7067","RMD.AU","BK7007","TLS.AU"],"gpt_icon":0},{"id":"2509256859","title":"Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2509256859","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509256859?lang=en_us&edition=fundamental","pubTime":"2025-02-06 02:59","pubTimestamp":1738781940,"startTime":"0","endTime":"0","summary":"Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share  of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles, amortization of Wilson Wolf intangible assets and acquired inventory and restructuring and restructuring-related costs among others.GAAP EPS was 22 cents compared with 17 cents in the prior-year quarter.Following the earnings announcement, shares of TECH rose 4.8% in pre-market trading today.Bio-Techne registered net sales of $297.0 million, up 9% year over year on a reported basis and 9% on an organic basis. The figure also topped the Zacks Consensus Estimate by 4.1%.Bio-Techne’s second-quarter fiscal 2025 adjusted earnings and revenues exceeded the respective Zacks Consensus Estimate. The company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bio-techne-tops-q2-earnings-185900309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DGX","TECH","CAH","RMD","RMD.AU"],"gpt_icon":1}],"pageSize":16,"totalPage":13,"pageCount":6,"totalSize":200}]}}